Richard Begent
Research Subjects
Research Interests
Richard Begent has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Gonzalez-Beltran
Oxford e-Research Centre, Department of Engineering Science, University of Oxford, Oxford, UK
1 shared publication Gairin Dancey
UCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UK
1 shared publication- Gairin Dancey
Cancer Institute, University College London, Huntley Street, London, UK
1 shared publication Kerry Chester
UCL Cancer Institute
1 shared publication- May Yong
Alan Turing Institute, London, UK
1 shared publication Michael Seckl
Dept. Medical Oncology, Charing Cross Campus of Imperial College, Fulham Palace Road, London W6 8RF, UK
1 shared publication
Latest Publications
- 20 March 2024
- Published by The Royal Society in Biographical Memoirs of Fellows of the Royal Society
- Vol. 76, 49-67
Kenneth Dawson Bagshawe. 17 August 1925—27 December 2022
Kenneth Bagshawe was a physician, a scientist and an architect of modern oncology. He was first to show that combination chemotherapy can cure a non-haematological cancer, choriocarcinoma. He demonstrated how a tumour marker in blood and urine can give a quantitative representation of the total amount of tumour, providing a monitor of response to treatment or relapse and an indicator of prognosis. He enhanced understanding and treatment of gestational trophoblastic diseases (GTD), a group of which choriocarcinoma is the most lethal member. The most common form of GTD is hydatidiform mole and he developed a national system for management, resulting in a cure rate of virtually 100%. For choriocarcinoma, the figure is today approaching 98%. His system is used in many countries, and over several decades has contributed to the cure and preservation of fertility in hundreds of thousands of women who previously had little or no hope. He used the same principles to treat testicular and ovarian germ cell tumours, again achieving high levels of cure in patients whose disease had spread and would previously have been fatal. He innovated throughout his career, seeking improved tumour specificity in diagnosis and treatment of GTD and inventing antibody-directed enzyme prodrug therapy for more common cancers. He founded the first department of oncology in the UK and devoted much time to developing the speciality, directing research funding organizations and supporting the development of the speciality worldwide. He was a dedicated, original and hugely productive pioneer of oncology.
- 20 March 2024
- Published by The Royal Society in Biographical Memoirs of Fellows of the Royal Society
- Vol. 76, 49-67
Kenneth Dawson Bagshawe. 17 August 1925—27 December 2022
Kenneth Bagshawe was a physician, a scientist and an architect of modern oncology. He was first to show that combination chemotherapy can cure a non-haematological cancer, choriocarcinoma. He demonstrated how a tumour marker in blood and urine can give a quantitative representation of the total amount of tumour, providing a monitor of response to treatment or relapse and an indicator of prognosis. He enhanced understanding and treatment of gestational trophoblastic diseases (GTD), a group of which choriocarcinoma is the most lethal member. The most common form of GTD is hydatidiform mole and he developed a national system for management, resulting in a cure rate of virtually 100%. For choriocarcinoma, the figure is today approaching 98%. His system is used in many countries, and over several decades has contributed to the cure and preservation of fertility in hundreds of thousands of women who previously had little or no hope. He used the same principles to treat testicular and ovarian germ cell tumours, again achieving high levels of cure in patients whose disease had spread and would previously have been fatal. He innovated throughout his career, seeking improved tumour specificity in diagnosis and treatment of GTD and inventing antibody-directed enzyme prodrug therapy for more common cancers. He founded the first department of oncology in the UK and devoted much time to developing the speciality, directing research funding organizations and supporting the development of the speciality worldwide. He was a dedicated, original and hugely productive pioneer of oncology.
- Open Access
- 6 January 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 10
Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy
Biology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.
- 6 January 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 10
Open AccessGuidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy
Biology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.
- 1 January 2010
- Published by Springer Nature
- Vol. 9 (3) , 431-451
Antibody-Dependent Enzyme Prodrug Therapy (ADEPT)
- 1 January 2010
- Published by Springer Nature
- Vol. 9 (3) , 431-451
Antibody-Dependent Enzyme Prodrug Therapy (ADEPT)
- 1 September 2009
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (3) , 201-217
Imaging in targeted delivery of therapy to cancer
We review the current status of imaging as applied to targeted therapy with particular focus on antibody-based therapeutics. Antibodies have high tumor specificity and can be engineered to optimize delivery to, and retention within, the tumor. Whole antibodies can activate natural immune effector mechanisms and can be conjugated to β- and α-emitting radionuclides, toxins, enzymes, and nanoparticles for enhanced therapeutic effect. Imaging is central to the development of these agents and is used for patient selection, performing dosimetry and assessment of response. γ- and positron-emitting radionuclides may be used to image the distribution of antibody-targeted therapeutics While some radionuclides such as iodine-131 emit both β and γ radiation and are therefore suitable for both imaging and therapy, others are more suited to imaging or therapy alone. Hence for radionuclide therapy of neuroendocrine tumors, patients can be selected for therapy on the basis of γ-emitting indium-111-octreotide imaging and treated with β-emitting yttrium-90-octreotate. Positron-emitting radionuclides can give greater sensitivity that γ-emitters but only a single radionuclide can be imaged at one time and the range of radionuclides is more limited. The multiple options for antibody-based therapeutic molecules, imaging technologies and therapeutic scenarios mean that very large amounts of diverse data are being acquired. This can be most effectively shared and progress accelerated by use of common data standards for imaging, biological, and clinical data.
- 1 September 2009
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (3) , 201-217
Imaging in targeted delivery of therapy to cancer
We review the current status of imaging as applied to targeted therapy with particular focus on antibody-based therapeutics. Antibodies have high tumor specificity and can be engineered to optimize delivery to, and retention within, the tumor. Whole antibodies can activate natural immune effector mechanisms and can be conjugated to β- and α-emitting radionuclides, toxins, enzymes, and nanoparticles for enhanced therapeutic effect. Imaging is central to the development of these agents and is used for patient selection, performing dosimetry and assessment of response. γ- and positron-emitting radionuclides may be used to image the distribution of antibody-targeted therapeutics While some radionuclides such as iodine-131 emit both β and γ radiation and are therefore suitable for both imaging and therapy, others are more suited to imaging or therapy alone. Hence for radionuclide therapy of neuroendocrine tumors, patients can be selected for therapy on the basis of γ-emitting indium-111-octreotide imaging and treated with β-emitting yttrium-90-octreotate. Positron-emitting radionuclides can give greater sensitivity that γ-emitters but only a single radionuclide can be imaged at one time and the range of radionuclides is more limited. The multiple options for antibody-based therapeutic molecules, imaging technologies and therapeutic scenarios mean that very large amounts of diverse data are being acquired. This can be most effectively shared and progress accelerated by use of common data standards for imaging, biological, and clinical data.
- 1 August 2009
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (8) , 755
Oncology Information Exchange opens up databases
- 1 August 2009
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (8) , 755
Oncology Information Exchange opens up databases
- 1 September 2007
- p. S53-8
Interpretation of treatment results with biological agents: is there a need for a new methodology?
The biological basis of cancer is progressively being demonstrated at a molecular level and it is possible to model the process of cancer and identify the points at which therapeutics can operate. With this knowledge of function, it is no longer satisfactory to assess response to therapy simply by change in dimensions of cancer. Genomic and proteomic analysis adds to conventional pharmacokinetics and pharmacodynamics in preclinical models and at selected points in clinical development but advances in functional imaging make this a key tool for assessing response to therapy. Functional analyses of computed tomography (CT) and magnetic resonance imaging (MRI) images can add important information about tumour patho-physiology and positron emission tomography (PET) and single photon emission tomography (SPECT) imaging make it possible to study the distribution and therapeutic function of drugs. Together these advances will improve clinical practice and facilitate effective and safe drug development.
- 1 September 2007
- p. S53-8
Interpretation of treatment results with biological agents: is there a need for a new methodology?
The biological basis of cancer is progressively being demonstrated at a molecular level and it is possible to model the process of cancer and identify the points at which therapeutics can operate. With this knowledge of function, it is no longer satisfactory to assess response to therapy simply by change in dimensions of cancer. Genomic and proteomic analysis adds to conventional pharmacokinetics and pharmacodynamics in preclinical models and at selected points in clinical development but advances in functional imaging make this a key tool for assessing response to therapy. Functional analyses of computed tomography (CT) and magnetic resonance imaging (MRI) images can add important information about tumour patho-physiology and positron emission tomography (PET) and single photon emission tomography (SPECT) imaging make it possible to study the distribution and therapeutic function of drugs. Together these advances will improve clinical practice and facilitate effective and safe drug development.